A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Nathan Clumeck Jean-Michel Molina Keith Henry Joseph Gathe Jürgen K Rockstroh Edwin DeJesus Xuelian Wei Kirsten White Marshall W Fordyce Martin S Rhee Javier Szwarcberg

J Acquir Immune Defic Syndr

*Maladies Infectieuses, Brussels, Belgium †Service de Maladies Infectieuses et Tropicales, Hospital Saint-Louis, AP-HP and University of Paris Sorbonne Cité, INSERM, Paris, France ‡Department of Infectious Diseases, Hennepin County Medical Center, Minneapolis, MN §Therapeutic Concepts, Houston, TX ‖Department of Medicine I, University of Bonn, Bonn, Germany ¶Orlando Immunology Center, Orlando, FL #Gilead Sciences, Foster City, CA.

Published: March 2014

Download full-text PDF	Source
http://dx.doi.org/10.1097/QAI.0000000000000089	DOI Listing

Publication Analysis

Top Keywords

randomized double-blind

double-blind comparison

comparison single-tablet

single-tablet regimen

regimen elvitegravir/cobicistat/emtricitabine/tenofovir

elvitegravir/cobicistat/emtricitabine/tenofovir ritonavir-boosted

ritonavir-boosted atazanavir

atazanavir emtricitabine/tenofovir

emtricitabine/tenofovir initial

initial treatment

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!